ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - tigecycline - אבקה מיובשת בהקפאה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

ישראל - עברית - Ministry of Health

סלע מדיקל בע"מ - אחות - monitoring intra-abdominal pressure

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - tigecycline - אבקה להכנת תמיסה לאינפוזיה - tigecycline 50 mg/dose - tigecycline - tigecycline - tygacil is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below for patients 18 years of age and older:complicated skin and skin structure infections:complicated skin and skin structure infections caused by escherichia coli, enterococcus faecalis (vancomycin-susceptible isolates ), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus agalactiae, streptococcus anginosus grp. (includes s. anginosus, s. intermedius, and s. constellatus), streptococcus pyogenes, enterobacter cloacae, klebsiella pneumoniae, and bacteroides fragilis .complicated intra-abdominal infections:complicated intra-abdominal infections caused by citrobacter freundii, enterobacter cloacae, escherichia coli, klebsiella oxytoca, klebsiella pneumoniae, enterococcus faecalis (vancomycin-susceptible isolates), staphylococcus aureus (methicillin-susceptible and -resistant isolates), streptococcus anginosus grp. (includes s. anginosu

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - ampicillin as sodium 500 mg; sulbactam as sodium 250 mg - powder for solution for injection - ampicillin and enzyme inhibitor - sulbactam sodium/ampicillin sodium im/iv is indicated for the treatment of infections due to susceptible beta-lactamase producing strains of microorganisms in the following conditions: 1) skin and skin structure infections. 2) intra-abdominal infections. 3) gynecological infections.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ampicillin as sodium; sulbactam as sodium - אבקה להכנת תמיסה לזריקה - ampicillin as sodium 1000 mg; sulbactam as sodium 500 mg - ampicillin and enzyme inhibitor - ampicillin and enzyme inhibitor - sulbactam sodium/ampicillin sodium im/iv is indicated for the treatment of infections due to susceptible beta-lactamase producing strains of microorganisms in the following conditions: 1) skin and skin structure infections. 2) intra-abdominal infections. 3) gynecological infections.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - ampicillin as sodium; sulbactam as sodium - אבקה להכנת תמיסה לזריקה - ampicillin as sodium 2000 mg; sulbactam as sodium 1000 mg - ampicillin and enzyme inhibitor - ampicillin and enzyme inhibitor - sulbactam sodium/ampicillin sodium im/iv is indicated for the treatment of infections due to susceptible beta-lactamase producing strains of microorganisms in the following conditions: 1) skin and skin structure infections. 2) intra-abdominal infections. 3) gynecological infections.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 500 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.

ישראל - עברית - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - meropenem as trihydrate - אבקה להכנת תמיסה לזריקה - meropenem as trihydrate 1000 mg/vial - meropenem - meropenem - meronem is indicated for treatment in adults and children of the following severe infections caused by single or multiple susceptible bacteria sensitive to meropenem: - pneumonias and nosocomial pneumonias. - pulmonary infections in patients with cystic fibrosis. - urinary tract infections. - intra-abdominal infections. - gynecological infections such as endometritis and pelvic inflammatory disease. - skin and skin structure infections. - meningitis. - septicemia. meronem has proved efficacious alone or in combination with other antimicrobial agents in the treatment of polymicrobial infections. there is no experience in pediatric patients with neutropenia or primary or secondary immunodeficiency.